Drug-Device Combination Products
Drug-Device Combination Products (DDCPs)—integrating pharmaceutical components with medical devices (e.g., drug-eluting stents, inhalers with proprietary formulations, injectable drug-delivery systems)—present unique clinical trial challenges: dual regulatory compliance, complex drug-device interaction assessment, and the need to validate both individual components and their synergistic performance. Meditronics, a core brand of STEMart, delivers tailored end-to-end clinical trial services engineered to address these intricacies, ensuring scientific rigor, regulatory adherence, and efficient product market access.
The clinical trial process for Drug-Device Combination Products comprises four specialized phases, each with distinct characteristics and critical considerations tied to their dual-component nature.
First-in-Human (FIH) Trials
Focuses on initial safety validation and drug-device compatibility, typically enrolling 20-50 healthy volunteers or a small cohort of target patients. Assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the combined product. Critical considerations include defining optimal drug-device pairing parameters and establishing standardized safety monitoring for device-related adverse events.
Pilot Trials
Expands to 100-300 subjects representing the target patient population, with dual goals of safety verification and preliminary efficacy assessment. Unique to combination products, this phase requires validating both the drug's therapeutic effect and the device's delivery performance. Endpoints may include drug bioavailability and user usability.
Pivotal Trials
Involves multi-center studies with 300-1,000 subjects, designed to confirm long-term safety, sustained efficacy, and real-world applicability. A key characteristic is the assessment of synergistic effects and long-term component stability—e.g., monitoring a drug-eluting stent's drug release over months and its impact on restenosis rates.
Post-Market Surveillance (PMS)
This phase focuses on real-world safety monitoring, including rare drug-device interaction events and long-term component performance (e.g., inhaler formulation stability over time).
End-to-End Clinical Trial Services
Meditronics, a brand of STEMart, offers a comprehensive, integrated service package covering every critical link of Drug-Device Combination Product clinical trials, with specialized expertise in navigating dual-component complexities.
Protocol Design
Leverages interdisciplinary teams (pharmaceutical scientists, device engineers, regulatory experts, statisticians) to develop scientifically robust plans addressing both drug and device requirements (e.g., ISO 10993 for biocompatibility, ICH-GCP for drug trials), in compliance with global standards (GCP, MDR, FDA, NMPA).
Ethics & Regulatory Strategy
Our team navigates ethical committee reviews efficiently, addressing key concerns including subject recruitment fairness, informed consent comprehensibility (disclosing dual-component risks), and privacy protection (per GDPR and HIPAA). For regulatory submission, we leverage deep expertise in FDA 510(k)/PMA, NMPA registration, and MDR processes, ensuring compliance with pre-market approval timelines for combination products.
Trial Site Selection
We partner with specialized expertise in combination product trials—evaluating factors such as investigator experience in both drug and device research, access to specialized testing equipment, and compliance track records.
Patient Recruitment
Leveraging disease-specific databases and patient advocacy groups,
Clinical Monitoring & Data Management
Treatment tracking includes real-time documentation of drug administration details, device parameters, and adverse events—with mandatory reporting of serious adverse events (SAEs) to regulatory authorities within 24 hours. Data management utilizes validated electronic data capture (EDC) systems with built-in logic checks for both drug and device data, audit trails, and encryption to ensure accuracy, completeness, and compliance with data privacy regulations
Post-Treatment Follow-Up
We design long-term follow-ups to assess combined product durability and real-world usability. To meet regulatory compliance requirements, maintain complete and auditable records of all follow-up data for inspections. For ethical obligations, promptly disclose new safety information to trial participants and ensure they receive necessary medical care for any adverse events related to either the drug or device component of the combination product.
DDCP Categories We Serve
Meditronics supports clinical trials for a wide range of DDCPs, including but not limited to:
- Implantable Drug-Device Combinations: Drug-eluting stents, biodegradable drug-eluting implants, hormonal intrauterine devices.
- Drug-Delivery Systems: Proprietary inhalers with fixed drug formulations, transdermal patches with controlled-release drugs, injectable pens with pre-measured drug doses.
- Minimally Invasive Combination Products: Drug-coated balloons, drug-eluting catheters, surgical mesh with antimicrobial agents.
- Topical/Aerosol Combination Products: Prescription skincare devices with drug-infused applicators, nebulizers with specialized drug formulations.
Our services cover both high-risk (Class III) and medium-risk (Class II) combination products, adapting to category-specific regulatory requirements—such as Class III implantables requiring more rigorous long-term data (per FDA 21 CFR Part 814) and drug-delivery systems complying with both pharmaceutical and device quality standards.
Why Partner with Meditronics for DDCP Trials?
Meditronics bridges the gap between drug and device development, delivering compliant, efficient trials for innovative combination products.
1. Dual-Expertise: Deep knowledge of both pharmaceutical (ICH, GMP) and device (ISO 13485, MDR) regulations.
2. Expert Professional Capabilities: Expert team with deep experience in cosmetic device trials, including knowledge of aesthetic evaluation methodologies, device-specific safety profiles, and global regulatory landscapes.
3. Stringent Compliance: We adhere to global standards (GCP, MDR, FDA, NMPA) and maintain full traceability of both drug and device data.
4. Efficient Execution: Our ability to coordinate multi-center trials, streamline recruitment, and resolve issues promptly ensures timely delivery of high-quality clinical data, accelerating product launch and market success.
Meditronics combines deep expertise in Drug-Device Combination Product trial uniqueities with uncompromising commitment to regulatory compliance and ethical standards. By integrating global regulatory requirements and dual-component safety/efficacy validation into every service link, we enable manufacturers to navigate the complex clinical trial landscape with confidence. Contact us today to accelerate your DDCP's clinical journey!
Online Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Need More Information or Request A Quotation?
Related Links
